Loading stock data…
Allogene Therapeutics, Inc. (ALLO)
$1.86-0.11 (-5.58%)
After Hours$1.88+0.02 (+0.94%)· Last close Sep 8
Allogene Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Allogene Therapeutics, Inc. in the Healthcare sector is trading at $1.97 with a market capitalization of $749M. Wall Street consensus targets $9.00 (9 analysts), implying a +356.9% move over the next 12 months. The stock is currently 56% below its 52-week high of $4.46, remaining 0.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +356.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.09M↓ | -$42.40M↑ | -$44.90M↑ | -$54.44M↑ | -$65.19M |
| Net Income | -$42.61M↓ | -$38.81M↑ | -$41.40M↑ | -$50.94M↑ | -$59.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CA...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$748.99M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.31%
Volume
Today's trading volume
7.43M
Recent News
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
Allogene (ALLO) Q2 2026 Earnings Call Transcript
Cema-cel hit 58.3% MRD negativity in ALPHA3 with zero treatment hospitalizations.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says
Allogene Therapeutics (ALLO) remains attractive given its undemanding valuation and differentiated c